US$ 29.65
dihexa human clinical trials data | Peptide Synthetic | High Purity EllieMD | Dihexa
Description
Most available research is preclinical, and human clinical data remain limited

An exemplary batch of gel formulation containing, for example, 1.5% of a JNK inhibitor described herein is prepared by dissolving Poloxamer 407 (BASF Corp.) in 50 mM Tris buffer and 77 mM NaCl solution with a pH between 5.5-8.0

The relevant buyers are Program Executive Offices, Combatant Commands, and prime contractors, and the vehicles include FAR contracts, production OTAs, and sole-source follow-on awards

Peptides also offer neuroprotective benefits, shielding the brain from damage caused by inflammation, oxidative stress, and other harmful factors
[PubMed: 20204458] 191
